Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …

Pulmonary hypertension is a progressive and often fatal cardiopulmonary condition
characterised by increased pulmonary arterial pressure, structural changes in the pulmonary …

Rationale: Pulmonary arterial hypertension (PAH) often results in death from right ventricular
failure (RVF). NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin …

Pulmonary arterial hypertension (PAH) is a severe disease with high morbidity and mortality.
Current therapies are mainly focused on vasodilative agents to improve prognosis …

Pulmonary hypertension (PH) is a progressive disease that arises from multiple etiologies
and ultimately leads to right heart failure as the predominant cause of morbidity and …

Pulmonary arterial hypertension (PAH), corresponding to group 1 of pulmonary
hypertension classification, is a rare disease with a major prognostic impact on morbidity …

Considerable progress has been made in the genomics of pulmonary arterial hypertension
(PAH) since the 6th World Symposium on Pulmonary Hypertension, with the identification of …

Pulmonary arterial hypertension is a chronic, progressive disorder of the pulmonary
vasculature with associated pulmonary and cardiac remodeling. PAH was a uniformly fatal …

Pulmonary hypertension (PH) is a condition characterized by changes in extracellular matrix
(ECM) deposition and vascular remodeling of distal pulmonary arteries. These changes …

Pulmonary hypertension (PH) is a progressive, pulmonary vascular disease with high
morbidity and mortality. Unfortunately, the pathogenesis of PH is complex and remains …